GLENMEDE TRUST CO NA APGE — APOGEE THERAPEUTICS INC

Ownership history in GLENMEDE TRUST CO NA  ·  9 quarters on record

AI Ownership Summary

GLENMEDE TRUST CO NA reported APOGEE THERAPEUTICS INC (APGE) in 9 quarterly 13F filings from 2024 Q2 through 2026 Q3. The latest visible filing shows APGE at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this APGE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was GLENMEDE TRUST CO NA's position in APOGEE THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q3

APGE was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q2 to 2026 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How GLENMEDE TRUST CO NA held APGE — position size vs. price
% of Fund (quarterly)    APGE price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 8 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q3 ADDED — — — 8,127 +2,007 +32.8% 0.00% $323K 2026-11-16 $135.07
2026 Q2 REDUCED — — — 6,120 -4,679 -43.3% 0.00% $812K 2026-08-10 $134.65
2026 Q1 ADDED — — — 10,799 +2,287 +26.9% 0.00% $909K 2026-05-26 $82.81
2025 Q4 ADDED — — — 8,512 +2,597 +43.9% 0.00% $642K 2026-02-17 $69.64
2025 Q1 REDUCED — — — 5,915 -8 -0.1% 0.00% $221K 2025-05-15 $40.64
2024 Q4 UNCHANGED — — — 5,923 — 0% 0.00% $268K 2025-02-14 $36.54
2024 Q3 REDUCED — — — 5,923 -137 -2.3% 0.00% $348K 2024-11-13 $52.79
2024 Q2 ADDED — — — 6,060 +178 +3.0% 0.00% $238K 2024-08-14 $44.23
1 older quarter hidden  —  Sign in free or upgrade to Premium to see full history

FAQ About GLENMEDE TRUST CO NA and APGE

These are the practical questions this page is built to answer before you even open the full history table.

How long has GLENMEDE TRUST CO NA reported owning APGE?

GLENMEDE TRUST CO NA reported APGE across 8 quarterly 13F filings, from 2024 Q2 through 2026 Q3.

What was the largest reported APGE position in GLENMEDE TRUST CO NA's portfolio?

The largest reported portfolio weight for APGE was 0.00% in 2026 Q1.

What is the latest reported APGE position on this page?

The most recent filing on this page is 2026 Q3, when GLENMEDE TRUST CO NA reported 8,127 shares, equal to 0.00% of portfolio, with an estimated market value of $323K.

What does the chart on this APGE ownership page compare?

The chart compares GLENMEDE TRUST CO NA's quarterly APGE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did GLENMEDE TRUST CO NA time their APGE position?

Based on 13F filing dates vs. subsequent APGE price moves, GLENMEDE TRUST CO NA correctly timed 4 out of 7 reported position changes (57%). The annualised alpha on APGE relative to SPY over the holding period was +11.0%.

← Back to GLENMEDE TRUST CO NA Holdings